FilingReader Intelligence
Amoytop Biotech subsidiary completes Skyline Therapeutics acquisition
July 30, 2025 at 05:28 PM UTC•By FilingReader AI
Xiamen Amoytop Biotech's subsidiary Bosai Gene completed its acquisition of certain assets from Skyline Therapeutics Limited on July 29, 2025. The transaction was funded using Bosai Gene's own resources.
The acquisition excludes assets of Skyline Therapeutics' US subsidiary and previously acquired assets.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:688278•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Xiamen Amoytop Biotech publishes news
Free account required • Unsubscribe anytime